Last week, Pfizer and BioNTech said their experimental COVID-19 vaccine was 90% effective in early interim results. And yesterday, they announced that their mRNA-based vaccine candidate is 95% effective at preventing COVID-19. Dr. Reynold Panettieri Jr. of Robert Wood Johnson Medical School, New Brunswick, New Jersey, told Medscape Medical News, “This is a game-changer. The Pfizer data hit the critical number of patients, that was 170, and showed 95% success, which was stunning data.” The clinical trial was ethnically diverse and its results were consistent across all genders and age groups, with a 94% efficacy seen in participants above 65 years of age. To read the full story.
Recent Posts
- Join NJ ACTS Special Populations Core Seminar Series on 4/30 at 1pm
- NJACTS Community Engagement Core COVID-19 Resources
- Long-Acting Opioids May Be Unnecessary in Study of Total Knee Replacement.
- Predicting Loneliness Through Online Digital Footprints.
- $265K Awarded to NJIT Researchers Via New Jersey Health Foundation Grants.
Categories
- News (2,125)
- Publication (1)